CD7 and AIDS: PAP-based immunotoxins were used in the treatment of AIDS patients and some of them (e.g., TXU (anti-CD7)-PAP) reached clinical trials where they reduced the viral burden in all HIV-1-infected adult patients without any adverse reactions.